Clinical Trial Update: Adjuvant Everolimus in High-Risk Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (SEVERANCE) is evaluating adjuvant everolimus in patients with high-risk hepatocellular carcinoma after curative resection; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Yonsei University | Conditions: Carcinom, Hepatocellular | Phase 2 | Status: NOT_YET_RECRUITING